Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1426 to 1440 of 1516 results for patients and public

  1. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued Reference number: GID-TA11244

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued Reference number: GID-TA11020

    Technology appraisal guidance
    Discontinued

  5. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued

  6. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development Reference number: GID-TA11401 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development Reference number: GID-TA11368 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development Reference number: GID-TA11265 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    In development Reference number: GID-TA11299 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

    Technology appraisal guidance
    In development